In the PARADISE-MI (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial Infarction) study, sacubitril/valsartan did not produce significant benefits compared to ramipril on the composite outcome of cardiovascular death, HF hospitalizations, or outpatient development of HF in patients with acute myocardial infarction [94]. The gene discussed is ACE; the disease is hydrops fetalis.